04:48 AM EDT, 07/15/2026 (MT Newswires) -- Nexstim (NXTMH.HE) secured an order for its Navigated Brain Stimulation 6 therapy system from an undisclosed neurology clinic in the US. The Finnish medical technology company will deliver an NBS 6 therapy base unit for therapeutic applications by the new client, according to a Wednesday release. In the US, the device is approved for the treatment of major depressive disorder and obsessive-compulsive disorder.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.